SCHEMBL29524280

SCHEMBL29524280

O=C1c2ccccc2-c2cc(Br)ccc21

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 4/20 0.83
S100A4 P26447 2/20 0.67
BCL2 P10415 2/20 0.61
MCL1 Q07820 1/20 0.61
MAPK1 P28482 5/20 0.58
CYP1A2 P05177 3/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
CDC25B P30305 1/20 0.55
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
APAF1 O14727 2/20 0.52
LMNA P02545 2/20 0.52
MAPT P10636 2/20 0.52
THRB P10828 2/20 0.52
HTT P42858 2/20 0.52
GALK1 P51570 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30523603 1.00 PTPRC (0.83) PTPRCS100A4BCL2MCL1MAPK1
SCHEMBL5273079 1.00 PTPRC (0.83) PTPRCS100A4BCL2MCL1MAPK1
SCHEMBL29827415 0.95 PTPRC (0.91) PTPRCS100A4BCL2MCL1MAPK1
SCHEMBL3948979 0.95 PTPRC (0.91) PTPRCS100A4BCL2MCL1MAPK1
SCHEMBL824162 0.95 PTPRC (0.91) PTPRCS100A4BCL2MCL1MAPK1
SCHEMBL29689751 0.95 PTPRC (0.91) PTPRCS100A4BCL2MCL1MAPK1
SCHEMBL391353 0.93 PTPRC (0.87) PTPRCS100A4BCL2MCL1MAPK1
Ammonia Solution, Strong SCHEMBL28061163 0.91 PTPRC (0.83) PTPRCS100A4BCL2MCL1MAPK1
SCHEMBL30987852 0.91 PTPRC (1.00) PTPRCS100A4BCL2MCL1MAPK1
SCHEMBL6259656 0.91 PTPRC (1.00) PTPRCS100A4BCL2MCL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
WO-2022186645-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER 엘티소재주식회사 2022-09-09 WO disclosed
WO-2022066774-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2022-03-31 WO disclosed